TrialInternational journal of clinical oncology2022

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).

Naoki Haratake et al.PubMed ↗Publisher ↗

No numbers read from the abstract.